Hallas J, Margulis AV, Pottegard A, Kristiansen NS, Atsma WJ, Appenteng K, de Vogel S, Kaye JA, Perez-Gutthann S, Arana A. Incidence of common cancers in users of antimuscarinic medications for overactive bladder: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):612-9. doi: 10.1111/bcpt.12965
Fernandez MM, Wang J, Ye X, Kwong WJ, Sherif B, Hogue S, Sherrill B. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score slanted greater than or equal to 2. SAGE Open Med. 2015 Dec. doi: 10.1177/2050312115613350
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.
Juniper M, Le TK, Mladsi D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother. 2009 Nov 1;10(16):2581-92. doi: 10.1517/14656560903304063.
Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life, and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature expert. Expert Opin Pharmacother. 2008 Apr;9(5):751-66.